M K Kirsten Chui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M K Kirsten Chui has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- John C. Newman
Buck Institute for Research on Aging, Novato, CA, USA
3 shared publications Birgit Schilling
Buck Institute for Research on Aging , Novato, California
1 shared publication- Colm Cunningham
School of Biochemistry and Immunology Trinity Biomedical Sciences Institute, Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland
1 shared publication - David Furman
Buck Institute for Research on Aging Novato California USA
1 shared publication Eric Verdin
Buck Institute for Research on Aging , Novato, California
1 shared publicationHeather Leutwyler
Department of Physiological Nursing, School of Nursing, University of California San Francisco
1 shared publication
Latest Publications
- Open Access
Ketone bodies mitigate against systemic inflammation-induced changes in brain energy metabolism and delirium-like deficits in aged mice
Acute systemic inflammation affects brain function, with detrimental consequences in aged individuals. These include delirium, an acute neuropsychiatric syndrome characterized by fluctuating disturbances in attention, perception and cognition. Delirium is associated with disrupted brain energy metabolism but our understanding of this during acute systemic inflammation is limited. Here we hypothesized that LPS-induced systemic inflammation would disrupt brain energy metabolism in aged C57BL6J mice and that the consequent functional impairments would be mitigated by ketone body utilization. We investigated ketone body effects in sickness behaviour, inflammation, energy metabolism and cognitive function. Real-time changes in utilisation of energy sources were quantified by indirect calorimetry and administration of radioisotope-labelled glucose and betahydroxybutyrate. Mass-spectrometry metabolomics was used to index severity of behavioural distrurbances to changes in hippocampal energy metabolism. LPS precipitated hypoglycemia and induced a whole-body switch from carbohydrate to lipid utilisation. Despite this, hippocampal insulin resistance and preserved brain glucose was observed while alternative carbohydrates, mannose and fructose, became depleted. Ketone ester treatment reversed insulin resistance, mitigated sickness behaviour and prevented delirium-like cognitive dysfunction without altering pro-inflammatory responses. Our results show that promoting ketone body usage mitigates systemic inflammation-induced brain energy disruption and prevents delirium-like cognitive deficits in aged mice.
Open AccessKetone bodies mitigate against systemic inflammation-induced changes in brain energy metabolism and delirium-like deficits in aged mice
Acute systemic inflammation affects brain function, with detrimental consequences in aged individuals. These include delirium, an acute neuropsychiatric syndrome characterized by fluctuating disturbances in attention, perception and cognition. Delirium is associated with disrupted brain energy metabolism but our understanding of this during acute systemic inflammation is limited. Here we hypothesized that LPS-induced systemic inflammation would disrupt brain energy metabolism in aged C57BL6J mice and that the consequent functional impairments would be mitigated by ketone body utilization. We investigated ketone body effects in sickness behaviour, inflammation, energy metabolism and cognitive function. Real-time changes in utilisation of energy sources were quantified by indirect calorimetry and administration of radioisotope-labelled glucose and betahydroxybutyrate. Mass-spectrometry metabolomics was used to index severity of behavioural distrurbances to changes in hippocampal energy metabolism. LPS precipitated hypoglycemia and induced a whole-body switch from carbohydrate to lipid utilisation. Despite this, hippocampal insulin resistance and preserved brain glucose was observed while alternative carbohydrates, mannose and fructose, became depleted. Ketone ester treatment reversed insulin resistance, mitigated sickness behaviour and prevented delirium-like cognitive dysfunction without altering pro-inflammatory responses. Our results show that promoting ketone body usage mitigates systemic inflammation-induced brain energy disruption and prevents delirium-like cognitive deficits in aged mice.
- 30 May 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (7)
Acute Nicotinamide Adenine Dinucleotide Supplementation via Nicotinamide Mononucleotide Does Not Rescue Functional Impairment in a Lipopolysaccharide-induced Delirium Mouse Model
Delirium is a serious neuropsychiatric condition that lacks an effective treatment intervention. A confusional state often brought on by acute illness, delirium is associated with acute inflammation and metabolic dysfunction. Nicotinamide adenine dinucleotide is a metabolite involved in both cellular energy generation and immunomodulation, that has previously been found to promote metabolic function and reduce inflammation. Whether Nicotinamide adenine dinucleotide supplementation may be beneficial for delirium has not been explored yet. In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model. While Nicotinamide adenine dinucleotide did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice, a comprehensive cytokine profile analysis did reveal rescue of plasma IFNγ levels by nicotinamide mononucleotide supplementation and partial improvement on the levels of IL-12p40, RANTES, LIX, and IL-17 which were sex-dependent.
- 30 May 2025
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 80 (7)
Acute Nicotinamide Adenine Dinucleotide Supplementation via Nicotinamide Mononucleotide Does Not Rescue Functional Impairment in a Lipopolysaccharide-induced Delirium Mouse Model
Delirium is a serious neuropsychiatric condition that lacks an effective treatment intervention. A confusional state often brought on by acute illness, delirium is associated with acute inflammation and metabolic dysfunction. Nicotinamide adenine dinucleotide is a metabolite involved in both cellular energy generation and immunomodulation, that has previously been found to promote metabolic function and reduce inflammation. Whether Nicotinamide adenine dinucleotide supplementation may be beneficial for delirium has not been explored yet. In this study, we investigate the effect of acute supplementation of nicotinamide mononucleotide, a direct precursor of Nicotinamide adenine dinucleotide, in a lipopolysaccharide-induced delirium mouse model. While Nicotinamide adenine dinucleotide did not rescue the delirium-like sickness behavior and metabolic dysfunction in mice, a comprehensive cytokine profile analysis did reveal rescue of plasma IFNγ levels by nicotinamide mononucleotide supplementation and partial improvement on the levels of IL-12p40, RANTES, LIX, and IL-17 which were sex-dependent.
- Open Access
Associations of Systemic Inflammation and Senescent Cell Biomarkers with Clinical Outcomes in Older Adults with Schizophrenia
Individuals with schizophrenia suffer from higher morbidity and mortality throughout life partly due to acceleration of aging-related diseases and conditions. Systemic inflammation is a hallmark of aging and is also observed in schizophrenia. An improved understanding of how inflammation and accelerated aging contribute to long-term health outcomes in schizophrenia could provide more effective treatments to preserve long-term cognitive and physical function. In this pilot cross-sectional study, 24 older adults (≥55 years old) with schizophrenia were assessed on symptoms (Positive and Negative Syndrome Scale), neurocognition (Matrics Consensus Cognitive Battery), mobility (Timed Get Up and Go), and general health (SF-12). Serum levels of 112 different cytokines were measured, from which we derived estimated senescence-associated secretory phenotype (SASP) scores for each participant. Two-tailed Pearson’s bivariate correlations were computed to test the associations between schizophrenia clinical outcomes with individual cytokines, and SASP. Higher levels of eotaxin, IL-1α, IL-1β, and IFNα are associated with both worse PANSS negative and depressive symptoms scores. IL-1α and IL-1β negatively associated with general physical health whereas eotaxin negatively associated with mobility and global cognition. Overall, we found that specific inflammatory cytokines, but not composite measurements of SASP, are associated with clinical outcomes in older adults with schizophrenia.
Open AccessAssociations of Systemic Inflammation and Senescent Cell Biomarkers with Clinical Outcomes in Older Adults with Schizophrenia
Individuals with schizophrenia suffer from higher morbidity and mortality throughout life partly due to acceleration of aging-related diseases and conditions. Systemic inflammation is a hallmark of aging and is also observed in schizophrenia. An improved understanding of how inflammation and accelerated aging contribute to long-term health outcomes in schizophrenia could provide more effective treatments to preserve long-term cognitive and physical function. In this pilot cross-sectional study, 24 older adults (≥55 years old) with schizophrenia were assessed on symptoms (Positive and Negative Syndrome Scale), neurocognition (Matrics Consensus Cognitive Battery), mobility (Timed Get Up and Go), and general health (SF-12). Serum levels of 112 different cytokines were measured, from which we derived estimated senescence-associated secretory phenotype (SASP) scores for each participant. Two-tailed Pearson’s bivariate correlations were computed to test the associations between schizophrenia clinical outcomes with individual cytokines, and SASP. Higher levels of eotaxin, IL-1α, IL-1β, and IFNα are associated with both worse PANSS negative and depressive symptoms scores. IL-1α and IL-1β negatively associated with general physical health whereas eotaxin negatively associated with mobility and global cognition. Overall, we found that specific inflammatory cytokines, but not composite measurements of SASP, are associated with clinical outcomes in older adults with schizophrenia.